The new evidence on the benefits of SGLT2 inhibitors in heart failure with mildly reduced or preserved ejection fraction, along with their favorable safety profile, the minimal requirement for monitoring, rapid onset of benefit, and beneficial effects on kidney function, supports prioritizing initiation of SGLT2 inhibitors in all HF patients26,50. This evidence concerns the gene SLC5A2 and heart failure.